Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts.

Respir Res 2018 01 26;19(1):20. Epub 2018 Jan 26.

Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 1830 E Monument St. 5th Floor, Baltimore, MD, 21287, USA.

Background: Thrombocytosis has been associated with COPD prevalence and increased all-cause mortality in patients with acute exacerbation of COPD (AECOPD); but whether it is associated with morbidity in stable COPD is unknown. This study aims to determine the association of thrombocytosis with COPD morbidity including reported AECOPD, respiratory symptoms and exercise capacity.

Methods: Participants with COPD were included from two multi-center observational studies (SPIROMICS and COPDGene). Cross-sectional associations of thrombocytosis (platelet count ≥350 × 10/L) with AECOPD during prior year (none vs. any), exertional dyspnea (modified Medical Research Council (mMRC) score ≥ 2), COPD Assessment Test (CAT) score ≥ 10, six-minute-walk distance (6MWD), and St. George Respiratory questionnaire (SGRQ) were modeled using multivariable logistic or linear regression. A pooled effect estimate for thrombocytosis was produced using meta-analysis of data from both studies.

Results: Thrombocytosis was present in 124/1820 (6.8%) SPIROMICS participants and 111/2185 (5.1%) COPDGene participants. In meta-analysis thrombocytosis was associated with any AECOPD (adjusted odds ratio [aOR] 1.5; 95% confidence interval [95% CI]: 1.1-2.0), severe AECOPD (aOR 1.5; 95% CI: 1.1-2.2), dyspnea (mMRC ≥ 2 aOR 1.4; 95% CI: 1.0-1.9), respiratory symptoms (CAT ≥ 10 aOR 1.6; 95% CI: 1.1-2.4), and higher SGRQ score (β 2.7; 95% CI: 0.5, 5). Thrombocytosis was also associated with classification into Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D (aOR 1.7 95% CI: 1.2-2.4).

Conclusions: Thrombocytosis was associated with higher likelihood of prior exacerbation and worse symptoms. Platelet count, a commonly measured clinical assay, may be a biomarker for moderate-severe COPD symptoms, guide disease classification and intensity of treatment. Future longitudinal studies investigating the role of platelets in COPD progression may be warranted.

Trial Registration: ClinicalTrials.gov: NCT01969344 (SPIROMICS) and NCT00608764 (COPDGene).

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12931-018-0717-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787242PMC
January 2018
14 Reads

Publication Analysis

Top Keywords

thrombocytosis associated
16
aor 95%
16
copd
9
thrombocytosis
8
platelet count
8
spiromics copdgene
8
respiratory symptoms
8
copd morbidity
8
association thrombocytosis
8
thrombocytosis copd
8
95%
6
associated
5
aecopd
5
95% confidence
4
[aor] 95%
4
confidence interval
4
interval [95%
4
[95% ci]
4
6mwd george
4
george respiratory
4

Altmetric Statistics

References

(Supplied by CrossRef)

L Huiart et al.
Chest 2005

DD Sin et al.
Proc Am Thorac Soc 2005

G Davì et al.
N Engl J Med 2007

K Ghoshal et al.
TheScientificWorldJOURNAL 2014

AI Schafer et al.
N Engl J Med 2004

J-F Viallard et al.
Blood 2002

K Kornerup et al.
Platelets 2007

VR Biljak et al.
Platelets 2011

P Ferroni et al.
J Investig Med 2000

MT Harrison et al.
Thorax 2014

JD Maclay et al.
Respirology 2007

Similar Publications